Navigation Links
ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
Date:9/17/2012

CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.  ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. 

(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D.   "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services.  Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays." 

These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative.  The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.

Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."

About ChanTest – The Ion Channel Expert

ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 

CONTACT: Chris Mathes, +1-732-586-1073

 


'/>"/>
SOURCE ChanTest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest hires Chris Mathes as Chief Commercial Officer
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. QBC Diagnostics Awarded GSA Contract
4. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
5. Northwest Bio Awarded $5.5 Million German Government Grant
6. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
7. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... May 22, 2017 , ... OSF Ventures, the corporate investment ... an early stage company in San Francisco that has developed software to individualize ... Innovation Fund acted as the lead investor in the round. , Medicine ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... ABC Financial Services and financial systems. , Dozens of clubs using ... that are electronically processed through GetLinked into their club’s accounting system , The ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... together a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity ... Equity is the third book from a recent series of from this ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from ... follow a protocol to quickly identify and treat the condition. , The mandate ... have saved Rory or anyone else’s life. , Now, five years after the ...
(Date:5/19/2017)... NC (PRWEB) , ... May 19, 2017 , ... ... the Charlotte health community, Queens University of Charlotte recently began recruitment efforts for ... program’s curriculum arms students with the skills, knowledge and expertise to approach and ...
Breaking Medicine News(10 mins):